(NASDAQ: SWTX) Springworks Therapeutics's forecast annual revenue growth rate of 60.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Springworks Therapeutics's revenue in 2025 is $219,670,000.On average, 5 Wall Street analysts forecast SWTX's revenue for 2025 to be $24,748,326,289, with the lowest SWTX revenue forecast at $24,143,183,749, and the highest SWTX revenue forecast at $25,416,137,311. On average, 4 Wall Street analysts forecast SWTX's revenue for 2026 to be $44,395,573,636, with the lowest SWTX revenue forecast at $37,882,796,726, and the highest SWTX revenue forecast at $54,022,944,025.
In 2027, SWTX is forecast to generate $69,069,179,810 in revenue, with the lowest revenue forecast at $59,938,788,569 and the highest revenue forecast at $85,208,046,623.